Tenax stock fell 84% to $2.

A single failed trial erased most of a public biotech’s value.

Levosimendan improved six-minute walk distance by just 14 meters versus 10.4 for placebo, missing significance, Tenax said.

No approved therapy exists for this form of heart failure, leaving the field open.

Sources: STAT